Philip Condon - True North MD Director
| TNC Stock | 3.00 2.97 9,900% |
Director
Philip Condon is MD Director of True North Copper
| Age | 59 |
| Address | Great Australia Mine, Cloncurry, QLD, Australia, 4824 |
| Phone | 61 7 4031 0644 |
| Web | https://truenorthcopper.com.au |
True North Management Efficiency
The company has return on total asset (ROA) of (0.1254) % which means that it has lost $0.1254 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6681) %, meaning that it generated substantial loss on money invested by shareholders. True North's management efficiency ratios could be used to measure how well True North manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Liabilities is likely to gain to about 20.1 M in 2024. Non Current Liabilities Total is likely to gain to about 35.2 M in 2024Similar Executives
| Found 3 records | DIRECTOR Age | ||
| Michael Poynton | MotorCycle Holdings | N/A | |
| Michael Baragwanath | Clime Investment Management | N/A | |
| William CFA | Clime Investment Management | N/A | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.13 |
True North Copper Leadership Team
Elected by the shareholders, the True North's board of directors comprises two types of representatives: True North inside directors who are chosen from within the company, and outside directors, selected externally and held independent of True. The board's role is to monitor True North's management team and ensure that shareholders' interests are well served. True North's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, True North's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rajesh Padmanabhan, Chief Officer | ||
| Peter Brown, Chief Officer | ||
| BB FAICD, Company CFO | ||
| Thomas Dwight, Exploration Mang | ||
| Martin Costello, MD Director | ||
| Philip Condon, MD Director | ||
| Bevan Jones, MD Director | ||
| ACA BSc, Chief Officer | ||
| MSc MSc, Operations Mang |
True Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is True North a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (3.62) % | ||||
| Current Valuation | 56.44 M | ||||
| Shares Outstanding | 15.38 M | ||||
| Shares Owned By Insiders | 35.34 % | ||||
| Shares Owned By Institutions | 18.53 % | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 0.19 X | ||||
| Revenue | 1.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for True Stock Analysis
When running True North's price analysis, check to measure True North's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy True North is operating at the current time. Most of True North's value examination focuses on studying past and present price action to predict the probability of True North's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move True North's price. Additionally, you may evaluate how the addition of True North to your portfolios can decrease your overall portfolio volatility.